103 filings
Page 3 of 6
DEFA14A
l1bxiz
24 Apr 20
Additional proxy soliciting materials
4:09pm
8-K
aq1zwl50zxw0cno
24 Mar 20
Other Events
6:06am
SEC STAFF
lqkhx5hs
28 Feb 20
SEC staff action: Order
12:00am
8-K
kviv 6ha7c9170
26 Feb 20
Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update
4:30pm
SEC STAFF
49ybm
3 Feb 20
SEC staff action: Order
12:00am
8-K
slbc6zq55ga4ryf
7 Jan 20
Departure of Directors or Certain Officers
4:48pm
8-K
lz1ox57ayvxinoer 353
17 Dec 19
Departure of Directors or Certain Officers
4:03pm
8-K
rlymvq egb2
18 Nov 19
Entry into a Material Definitive Agreement
8:01am
8-K
ontpxrf h1
31 Oct 19
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update
4:30pm
8-K
hk26zj wny5sep849v
13 Sep 19
Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares
4:05pm
8-K
vpkpysblq2hjfbw
11 Sep 19
Entry into a Material Definitive Agreement
4:36pm
EFFECT
6fqobnzn dj
4 Sep 19
Notice of effectiveness
12:15am
CORRESP
mtpj3h9aqkmltl fo
27 Aug 19
Correspondence with SEC
12:00am
S-3/A
ic5tphtu
23 Aug 19
Shelf registration (amended)
4:07pm
CORRESP
mfeu6 kp1qqf52ovk
23 Aug 19
Correspondence with SEC
12:00am
UPLOAD
man9wk0z zv
13 Aug 19
Letter from SEC
12:00am
8-K
6ib7dgy6co
12 Aug 19
Eidos Therapeutics Confirms Receipt ofNon-Binding Proposal from BridgeBio Pharma to Acquire Shares
4:27pm